Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Lim, Do H ^b   Park, Se H ^a   Park, Keon W ^b   Kang, Jung H ^c   Oh, Sung Y ^d   Hwang, In G ^e   Kwon, Jung M ^f   Lee, Sang Cheol ^g   Lee, Hui Young ^h   Kim, Hyeong S ⁱ   Lim, Ho Y ^a   Kang, Won K ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Dankook University   (South Korea)

^c Gyeongsang National University   (South Korea)

^d Dong A University College of Medicine   (South Korea)

^e Chung Ang University College of Medicine   (South Korea)

^f Jeju National University School of Medicine   (South Korea)

^g Soonchunhyang University College of Medicine   (South Korea)

^h Kangwon National University   (South Korea)

ⁱ Hallym University Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CISPLATIN; DOCETAXEL; FLUOROURACIL; HEMOGLOBIN; PACLITAXEL; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CENTER; CANCER REGISTRY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GASTRECTOMY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STOMACH CANCER; TREATMENT OUTCOME; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; STOMACH TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PACLITAXEL; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 77958146798     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-583     Document Type: Article

References (25)

1. Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, Park EC, Ahn YO, Hwang IK, Lee DH, et al. Nationwide Cancer Incidence in Korea, 2003-2005. Cancer Res Treat 2009, 41(3):122-131. 10.4143/crt.2009.41.3.122, 2757659, 19809561.
2. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995, 71(3):587-591. 2033628, 7533517.
3. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997, 8(2):163-168. 10.1023/A:1008243606668, 9093725.
4. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 2006, 24(14):2188-2196. 10.1200/JCO.2006.05.9758, 16682738.
5. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358(1):36-46. 10.1056/NEJMoa073149, 18172173.
6. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009, 20(4):666-673. 10.1093/annonc/mdn717, 19153121.
7. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008, 9(3):215-221. 10.1016/S1470-2045(08)70035-4, 18282805.
8. Park SH, Kang WK, Lee HR, Park J, Lee KE, Lee SH, Park JO, Kim K, Kim WS, Chung CW, et al. Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. Am J Clin Oncol 2004, 27(5):477-480. 10.1097/01.coc.0000136018.81814.79, 15596914.
9. Park KW, Ahn JS, Park YS, Lee J, Kang JH, Park JO, Lim HY, Im YH, Kang WK, Park K, et al. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. Cancer Chemother Pharmacol 2007, 59(1):17-21. 10.1007/s00280-006-0253-2, 16721549.
10. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006, 24(31):4991-4997. 10.1200/JCO.2006.06.8429, 17075117.
11. Yun J, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J Cancer 2010, 46(5):885-891. 10.1016/j.ejca.2009.12.015, 20060288.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216. 10.1093/jnci/92.3.205, 10655437.
13. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24(18):2903-2909. 10.1200/JCO.2005.05.0245, 16782930.
14. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004, 22(12):2395-2403. 10.1200/JCO.2004.08.154, 15197201.
15. Lee J, Lim T, Uhm J, Park K, Park S, Lee S, Park J, Park Y, Lim H, Sohn T, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 2007, 18(5):886-891. 10.1093/annonc/mdl501, 17298958.
16. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F, Ferraraccio F. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007, 31(7):1458-1468. 10.1007/s00268-007-9016-4, 17516110.
17. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008, 15(1):69-79. 10.1245/s10434-007-9596-0, 17896140.
18. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006, 51(8):1371-1379. 10.1007/s10620-005-9057-1, 16868827.
19. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, et al. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 2008, 98(4):832-839. 10.1038/sj.bjc.6604211, 2259181, 18231104.
20. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26(3):374-379. 10.1200/JCO.2007.12.5906, 18202412.
21. Lee KH, Lee JS, Suh C, Kim SW, Kim SB, Lee JH, Lee MS, Park MY, Sun HS, Kim SH. Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. Cancer 1995, 75(12):2794-2801. 10.1002/1097-0142(19950615)75:12<2794::AID-CNCR2820751203>3.0.CO;2-F, 7773929.
22. Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M, Caporaso NE, Fraumeni JF, Rice JM. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res 1995, 55(12):2665-2672.
23. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008, 26(9):1435-1442. 10.1200/JCO.2007.13.9378, 18349393.
24. Cvitkovic E. Ongoing and unsaid on oxaliplatin: the hope. Br J Cancer 1998, 77(Suppl 4):8-11. 2149881, 9647613.
25. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009, 27(18s). abstr LBA4509.